|
MechanismDPP-4 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date18 Oct 2023 |
100 Clinical Results associated with Revio Therapeutics LLP
0 Patents (Medical) associated with Revio Therapeutics LLP
100 Deals associated with Revio Therapeutics LLP
100 Translational Medicine associated with Revio Therapeutics LLP